Science & Enterprise subscription

Follow us on Twitter

  • In one of its first actions, the Biden administration rejoined the United States in the World Health Organization,… https://t.co/gpHTTr70DP
    about 13 hours ago
  • New post on Science and Enterprise: U.S. Rejoins WHO, Participates in Int’l Vaccine Project https://t.co/bBUZr5UzSg #Science #Business
    about 13 hours ago
  • A clinical trial shows long-term care residents and staff receiving a synthetic antibody treatment have a lower ris… https://t.co/EPYrP8wElE
    about 17 hours ago
  • New post on Science and Enterprise: Antibodies Prevent Covid-19 Symptoms in Long-Term Care https://t.co/sePqojZMVd #Science #Business
    about 17 hours ago
  • Another way to connect 100 million people end-to-end with Covid-19 vaccines. https://t.co/wIWk0XNDhv
    about 1 day ago

Please share Science & Enterprise

Drug Price Disruptor Biotech Raises $500M in New Funds

Pills and dollar bill

A start-up biotechnology company that aims to bring drugs to market at lower cost is raising $500 million in its second venture funding round. . . . → Read More: Drug Price Disruptor Biotech Raises $500M in New Funds

Digital Therapeutics Designed for Cancer/Covid-19 Stress

Man with depression

A digital health company is partnering with cancer advocacy organizations to provide electronic therapies to help patients deal with stresses from Covid-19. . . . → Read More: Digital Therapeutics Designed for Cancer/Covid-19 Stress

Vaccine Shown Active Against New Covid-19 Variants

mRNA vaccine graphic

A current Covid-19 vaccine is shown in lab tests to produce antibodies that appear to protect against new mutations found in South Africa and the U.K. . . . → Read More: Vaccine Shown Active Against New Covid-19 Variants

CureVac, Bayer Partner on Covid-19 Vaccine Supply

Syringe in hand

Vaccine developer CureVac and global drug maker Bayer are partnering on further development, authorization, and supply of CureVac’s Covid-19 vaccine. . . . → Read More: CureVac, Bayer Partner on Covid-19 Vaccine Supply

Synthetic Biology Company Raises $105M in New Funds

DNA chip graphic

A company developing cellular and genetic therapies for cancer designed like electronic circuits is raising $105 million in its second venture round. . . . → Read More: Synthetic Biology Company Raises $105M in New Funds

Stem Cells Help Severe Covid-19 Cases Recover

lung illustration

Results of a clinical trial show stem cells from umbilical cord linings help patients with severe respiratory disease recover and survive from Covid-19 infections. . . . → Read More: Stem Cells Help Severe Covid-19 Cases Recover

Synthetic Virus Company Forms, Raises $77M

Adenovirus schematic

A new biotechnology enterprise is underway that develops synthetic viruses attacking solid tumor cancers, based on research at the Salk Institute. . . . → Read More: Synthetic Virus Company Forms, Raises $77M

AI Process Devised for Drug Repurposing

Network pointer

A biomedical informatics lab developed techniques with artificial intelligence to find new uses for existing drugs from millions of electronic health records. . . . → Read More: AI Process Devised for Drug Repurposing

FDA Issues Precision Genomic Drug Guidance

DNA analysis graphic

The U.S. Food and Drug Administration issued draft administrative and procedural guidelines for genetic disorders treated with precise gene therapies. . . . → Read More: FDA Issues Precision Genomic Drug Guidance

Trial OKed for Rare Disease Gene Therapy

Nerve cells illustration

A start-up biotech company says it received clearance from the Food and Drug Administration to begin a clinical trial of its gene therapy for Krabbe disease. . . . → Read More: Trial OKed for Rare Disease Gene Therapy